Transforming Intermittent preventive treatment for optimal pregnancy (TIPTOP)

The devastating consequences of malaria disproportionately affect pregnant women and their newborns. Lowered immunity due to malaria in pregnancy leads to higher rates of severe maternal anaemia and low birth weight. Malaria in pregnancy is responsible for 10,000 maternal deaths and 100,000 newborn deaths each year. Despite the availability of affordable interventions and medicines to prevent malaria in pregnancy, a high proportion of pregnant women do not access them.

The TIPTOP project approach is simple and innovative—introducing community-level distribution of quality-assured (QA) SP and expanding antenatal care attendance. The project, managed and implemented by Jhpiego, will substantially reduce missed opportunities for eligible pregnant women to receive SP by helping to reach those most vulnerable in four African countries—the Democratic Republic of Congo, Madagascar, Mozambique and Nigeria.

TIPTOP will drive impact in target countries and regionally to help countries significantly increase SP coverage. This innovative, community-based approach promotes early and comprehensive antenatal care attendance. The approach reinforces the new WHO antenatal care recommendations of eight contacts between pregnant women and the health system to ensure that pregnant women receive IPTp-SP when eligible. TIPTOP aims to dramatically reduce malaria-related deaths of mothers and newborns across Africa and steer advancements in malaria in pregnancy at the global, regional and country levels—ultimately saving the lives of thousands of mothers and newborns.

Clinical trial Id: NCT03600844

TIPTOP WebsiteTIPTOP Clinical trial registration

Drug-based Strategies
Vulnerable Populations

Sep 2017 — Sep 2022

$49.65M

Dem. Rep. of Congo
Madagascar
Mozambique
Nigeria

Intermittent preventive treatment in pregnancy (IPTp)
Tracking progress against the PMI Insights Research Priorities